Leading policy-makers and scholars explain how market forces, deregulation, and consumer choice can work to improve health care for all Americans.


The New Heart Disease Threat
The New York Times, 1-11-05

The New York Times acknowledges that “[t]he evidence has gotten much stronger that a substance known as C-reactive protein [CRP] may be every bit as important as cholesterol in the diagnosis and treatment of heart disease” in light of two studies recently published in the The New England Journal of Medicine. The studies have also “shown that drugs that reduce the levels of that protein in patients with severe heart disease can slow the progression of atherosclerosis and prevent heart attacks and cardiac related deaths.”

We would also add that the flurry of studies on different statins, and new discoveries on the underlying biology of heart disease are being funded by pharmaceutical companies eager to prove the utility of their medicines – and profit by it.

A perfect match between the market and medical progress.

Project FDA.
home   spotlight   commentary   research   events   news   about   contact   links   archives
Copyright Manhattan Institute for Policy Research
52 Vanderbilt Avenue
New York, NY 10017
(212) 599-7000